EuCorVac-19
This is an old revision of this page, as edited by Citation bot (talk | contribs) at 11:39, 2 November 2022 (Alter: template type. Add: date. | Use this bot. Report bugs. | Suggested by Anas1712 | #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[1][2][3][4]
Clinical trials
Phase I/II
EuBiologics Co., Ltd started the study on February 23, 2021.[5] The study is called "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults"[5] As of April 26, 2021, the trial is ongoing and participants are being accepted. It has an expected primary completion date of March 2022. The study is expected to be completed in January of 2023.
Phase III
EuBiologics registered a phase III trial with a starting date of October 1, 2022 in the Philippines.[6]
References
- ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. Retrieved 17 April 2021.
- ^ Moon-hee C (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine 'EuCOVAC-19'". Business Korea. Retrieved 17 April 2021.
- ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. Retrieved 17 April 2021.
- ^ "Firm looks to build vaccine manufacturing plant in PH". ABS-CBN News. 12 April 2021. Retrieved 17 April 2021.
- ^ a b "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
{{cite web}}
: CS1 maint: url-status (link) - ^ "A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults". ClinicalTrials.gov. National Institutes of Health. 27 October 2022. Retrieved 30 October 2022.
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- CS1 maint: url-status
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles